Markets
markets
Max Knoblauch

Match Group climbs as CEO touts Tinder turnaround plan

Match Group is rising in early trading on Wednesday following the Tuesday release of its fourth-quarter earnings report.

Match issued lackluster full-year revenue guidance of between $3.41 billion and $3.54 billion for 2026, below the $3.59 billion estimate from Wall Street analysts polled by FactSet. Still, investors appear drawn to the company’s Tinder turnaround plans.

On Match’s earnings call, CEO Spencer Rascoff said its 2026 Tinder road map directly addresses Gen Z pain points. Discovery will be redesigned to be “more expressive and less repetitive,” and verification and safety will be strengthened.

Paid users on Tinder fell 8% in the fourth quarter to 8.8 million. Paid users on Hinge grew 17% to 1.9 million. Match has reportedly budgeted $60 million for AI and product rollouts at its popular dating app.

“I’m confident that by the end of this year, the product will feel meaningfully different,” Rascoff said.

More Markets

See all Markets
markets
Luke Kawa

Broadcom soars on Google’s plans for up to $185 billion in capex this year

Google’s capex guidance is Broadcom’s earnings guidance.

The hyperscaler and search giant said its 2026 capex budget would be between $175 billion and $185 billion, 55% higher than Wall Street had anticipated.

Accordingly, shares of the custom chip specialist are soaring in after-hours trading.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

But the custom chip designer had tumbled after its most recent earnings report, with some analysts attributing the decline to the dearth of new customer announcements. But who needs new customers when your current ones are opening their wallets this much?!?

Alphabet beat earnings and revenue expectations

Alphabet beat earnings and revenue expectations

Accordingly, shares of the custom chip specialist are soaring in after-hours trading.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

But the custom chip designer had tumbled after its most recent earnings report, with some analysts attributing the decline to the dearth of new customer announcements. But who needs new customers when your current ones are opening their wallets this much?!?

Luke Kawa
2h
Qualcomm tumbles after releasing gloomy Q2 guidance thanks to memory chip supply crunch

Q1 results beat expectations, but the memory chip crunch looks to be weighing on the forward outlook.

A crowd of visitors at the Qualcomm ( Qualcomm is an...
Tasha Matsumoto
2h
Stocks continue to slide amid tech sell-off

Investors were once again in risk-off mode as tech and crypto continued to fall.

Chicago Bears fans react during the second half of a game against the Arizona Cardinals at State Farm Stadium on November 03, 2024 in Glendale, Arizona.
(J. Edward Moreno/Sherwood News)

Novo and Lilly agree prices are falling — and disagree on what comes next

Novo Nordisk and Eli Lilly are cutting prices to reach more patients — with sharply different expectations about what that means for sales.

J. Edward Moreno3h
markets
J. Edward Moreno

Ozempic is no longer the most searched for GLP-1 in the US

Ozempic, the popular diabetes drug made by Novo Nordisk, used to be shorthand for an entire class of diabetes and weight-loss medications. Not anymore.

According to Google Trends data, as of January, more people in the US are searching for Eli Lilly’s weight-loss shot, Zepbound, than Ozempic. At the same time, interest in the word “Ozempic” now sits roughly on par with searches for “peptides,” a catchall term for a booming, loosely regulated category of experimental supplements.

The numbers hint at a cultural shift: Ozempic is no longer the only word people reach for when they think about weight-loss drugs. The market — and the vocabulary around it — is fragmenting.

This shift also reflected in sales numbers. For several quarters now, Lilly’s diabetes and weight-loss drugs have outsold Novo’s, and that gap is expected to widen this year.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.
©2026 Sherwood Media, LLC